Regulators have taken notice after a study sparked fresh doubts over the usefulness of a Covid drug made by US pharma group Merck, raising questions about the costly procurement of antivirals during the peak of the pandemic.
The Medicines and Healthcare products Regulatory Agency, the UK drugs watchdog, is assessing whether conditional marketing authorisation should be renewed for Merck’s molnupiravir, also known by the trade name Lagevrio.
“We continue to seek advice from the independent scientific advisory body, the Commission on Human Medicines,” it told the Financial Times. “Patient safety is our top priority and we are closely assessing the data to ensure that the benefits of Lagevrio outweigh the risks.”
您已阅读16%（717字），剩余84%（3646字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。